Drugs /

e7820

Back to Drugs List

Overview

NCI Definition [1]:
A small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.

Clinical Trials

View Clinical Trials for e7820

E7820 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating e7820, 1 is phase 2 (1 open).

PML-RARA Fusion, SF3B1 Mutation, and SRSF2 Mutation are the most frequent biomarker inclusion criteria for e7820 clinical trials.

Acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndromes are the most common diseases being investigated in e7820 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating E7820
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating e7820 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
integrin alpha-2 inhibitor e7820, n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide
Drug Target(s) [2]:
ITGA2
NCIT ID [1]:
C61501

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.